Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection

Infection and Immunity

Volumn 66, Issue 10, 1998, Pages 5027-5030

  Rivera, Johanna ^a   Feldmesser, Marta ^a   Cammer, Michael ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ARTICLE; BRAIN; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; EXPERIMENTAL INFECTION; FUNGUS GROWTH; GENE EXPRESSION REGULATION; LUNG; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL;

CRYPTOCOCCUS NEOFORMANS;

EID: 0031692325     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.10.5027-5030.1998     Document Type: Article

References (18)

1. Bulmer, G. S., M. D. Sans, and C. M. Gunn. 1967. Cryptococcus neoformans, I. Nonencapsulated mutants. J. Bacteriol. 94:1475.
2. L usage in polysaccharide binding antibodies. J. Exp. Med. 174:151-160.
3. Casadevall, A., J. Mukherjee, N. Devi, R. Schneerson, J. B. Robbins, and M. D. Scharff. 1992. Antibodies elicited by Cryptococcus neoformans glucuronoxylomannans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 65:1086-1093.
4. Casadevall, A., J. Mukherjee, and M. D. Scharff. 1992. Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J. Immunol. Methods 154:27-35.
5. Cherniak, R., E. Rciss. and S. H. Turner. 1982. A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr. Res. 103:239-250.
6. Cherniak, R., and J. B. Sundstrom. 1994. Polysaccharide antigens of the capsule of Cryptococcus neofonnans. Infect. Immun. 62:1507-1512.
7. Currie, B. P., and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin. Infect. Dis. 19:1029-1033.
8. Erb. G. L., D. L. Osterbur, and S. M. LeVine. 1996. The distribution of iron in the brain: a phylogenetic analysis using iron histochemistry, Dev. Brain Res. 93:120-128.
9. Feldmesser, M., and A. Casadevall. 1997. Effect of serum IgG1 to Cryptococcus ncoformans glucuronoxylomannan on murine pulmonary infection. J. Immunol. 158:790-799.
10. Goldman, D. L., S. P. Franzot, and A. Casadevall. 1997. Phenotypic switching in Cryptococcus ncofonnans, abstr. F-44. p. 267. In Abstracts of the 97th General Meeting of the American Society for Microbiology 1997. American Society tor Microbiology, Washington, D.C.
11. Goldman, D. L., S. C. Lee, and A. Casadevall. 1995. Tissue localization of Cryptococcus neofonnans glucuronoxylomannan in the presence and absence of specific antibody. Infect. Immun. 63:3448-3453.
12. Guyton, A. C. 1986. Physical principles of gaseous exchange: diffusion of oxygen and carbon dioxide through the respiratory membrane, p. 481-503. In D. Dreibelbis (ed.), Textbook of medical physiology. W. B. Saunders Co., Philadelphia, Pa.
13. Lendvai, N., A. Casadevall, Z. Liang, D. L. Goldman, J. Mukherjee, and L. Zuckier. 1998. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J. Infect. Dis. 177:1647-1659.
14. Levitz, S. M., D. J. DiBenedetto, and R. D. Diamond. 1987. A rapid fluorescent assay to distinguish attached from phagocytized yeast particles. J. Immunol. Methods 101:37-42.
15. Littman, M. L. 1958. Capsule synthesis by Cryptococcus neofonnans. Trans. N. Y. Acad. Sci. 20:623-648.
16. Littman, M. L., and E. Tsubura. 1959. Effect of degree of encapsulation upon virulence of Cryptococcus neofonnans. Proc. Soc. Exp. Biol. Med. 101:773-777.
17. Morris, C. M., J. M. Candy, A. E. Oakley, C. A. Bloxham, and J. A. Edwardson. 1992. Histochemical distribution of non-haem iron in the human brain. Acta Anal. 144:235-257.
18. Nussbaum, G., W. Clears, A. Casadevall, M. D. Scharff, and P. Valadon. 1997. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J. Exp. Med. 185:685-694.